Cipla, a global pharmaceutical company, has entered into a strategic collaboration with Kemwell Biopharma and Manipal Education & Medical Group to establish a joint venture in the United States. This joint venture aims to focus on the development and commercialization of innovative cell therapy products to address significant unmet medical needs in the US, Japan, and EU regions.
As part of the collaboration, Cipla (EU), a wholly-owned subsidiary of Cipla, will hold a 35% stake in the joint venture company. The collaboration brings together Cipla’s expertise in product development and commercialization, Kemwell’s proficiency in biologics, and Manipal’s experience in healthcare delivery.
The joint venture is strategically positioned to expedite the development, manufacturing, licensing, import, and export of cutting-edge cell therapy products. This collaboration reflects Cipla’s commitment to advancing innovation in areas such as stem cell and CAR T-cell therapies, leveraging advancements in biotech, mRNA, and cell-engineering research.
Umang Vohra, Managing Director & Global CEO of Cipla, emphasized the joint venture’s role in pushing the boundaries of innovation and pioneering transformative treatments. The collaboration is expected to contribute to the global advancement of cell therapies, addressing unmet medical needs and providing physicians with accessible, safe, and clinically effective solutions for various indications.
This venture builds on the success of a previous collaboration between Cipla and Kemwell Biopharma, which led to the incorporation of Aspergen Inc. in 2022. The earlier joint venture focused on the development, manufacturing, and commercialization of biosimilars for global markets. The current partnership further solidifies the relationship between the two entities and expands their collaborative efforts into the promising field of cell therapy.
Cell therapy products are anticipated to play a transformative role in providing advanced therapeutic treatments for patients grappling with various challenging diseases. The synergies between Cipla, Kemwell, and Manipal are expected to drive the accelerated development of novel cell-based products, positioning the joint venture as a global player in the field of cell therapeutics.
